GMO US Quality ETF Underperforms, Hold Rating Maintained
Finance

GMO US Quality ETF Underperforms, Hold Rating Maintained

authorBy Strive Masiyiwa
DateMay 23, 2026
Read time3 min

The GMO U.S. Quality ETF (QLTY) is an actively managed fund that employs a sophisticated strategy combining fundamental and quantitative methods. However, despite its impressive quality characteristics, the ETF has recently underperformed its benchmark, the IVV. This analysis delves into the reasons behind this underperformance, highlighting concerns regarding QLTY's risk metrics, such as its tendency for deep maximum drawdowns and a high downside capture. The current market conditions, characterized by high valuations, suggest that QLTY is unlikely to outperform IVV by year-end, leading to a maintained "Hold" rating. While the fund is worth monitoring for future developments, it does not currently present a compelling investment opportunity for outperformance.

GMO U.S. Quality ETF Faces Challenges Amid Market Dynamics

In a recent assessment, the GMO U.S. Quality ETF (QLTY), an actively managed investment vehicle that blends both fundamental and quantitative analysis, has been re-evaluated. Despite the inherent strength in its quality-focused portfolio, the ETF has demonstrated a pattern of underperformance when compared to its benchmark, the iShares Core S&P 500 ETF (IVV).

Key findings from the analysis reveal that QLTY's portfolio, while strong in quality metrics, does not consistently translate into superior market performance. A significant contributing factor to this outlook is the ETF's risk profile, characterized by a notable propensity for substantial maximum drawdowns and a downside capture ratio exceeding 100%. These indicators suggest that QLTY tends to capture more of the market's downturns than its upside potential, making it a less-than-ideal option in the current market environment, which is perceived as high-priced.

The current recommendation for QLTY remains a "Hold" rating. This stance is primarily due to its recent comparative underperformance against IVV, coupled with its unappealing risk metrics and a factor mix that is not heavily weighted towards growth at a reasonable price (GARP) stocks. Investors are advised to observe QLTY's trajectory, but no immediate outperformance against IVV is anticipated for the remainder of the year. The ETF's strategic approach, while robust in theory, has yet to consistently deliver market-beating returns, prompting a cautious outlook from analysts.

This re-evaluation of QLTY serves as a pertinent reminder that even strategies built on strong fundamental principles, when combined with sophisticated quantitative models, may not always guarantee market outperformance. The interplay of market dynamics, risk management, and the prevailing economic climate significantly influences an investment's trajectory. For investors, this highlights the importance of not only scrutinizing a fund's investment philosophy but also rigorously assessing its historical performance against benchmarks and its inherent risk characteristics. In a dynamic and often unpredictable market, a balanced perspective that acknowledges both potential and pitfalls is crucial for informed decision-making. The ongoing monitoring of funds like QLTY is essential, as market conditions and fund performance can evolve, potentially altering their investment appeal.

More Articles
Finance
Akre Capital Management's Investment Shifts in Q1 2026
Akre Capital Management's Q1 2026 13F portfolio saw a value reduction to approximately $6.13 billion. Key adjustments included notable reductions in long-standing successful investments such as MasterCard, Brookfield, and KKR, indicating a strategy of capitalizing on prior gains. The firm also introduced new positions in Salesforce, ServiceNow, and Perimeter Solutions, while completely divesting from Danaher and CarMax. Simultaneously, Akre increased its stakes in companies like Roper, CoStar, Fair Isaac, Copart, and CCC Intelligent Solutions, reflecting a dynamic re-evaluation of its investment priorities.
By Mariana MazzucatoMay 23, 2026
Finance
Dividend Investment Highlights: Weekly Update
This report provides a concise summary of recent changes and key dates for Dividend Champion, Contender, and Challenger companies. It covers firms with altered dividend payouts, as well as those approaching ex-dividend and pay dates, offering essential, up-to-date information for dividend investors.
By Fareed ZakariaMay 23, 2026
Finance
Barron's Dividend Dogs: May 2026 Oil & Blue Chip Picks
Barron's Oil & Blue Chip Tips for May 2026 identifies 20 stocks, with 11 categorized as 'safer' based on free cash flow yields surpassing dividend yields. The top ten yield picks are projected to achieve average net gains of 36.08% by May 2027, with volatility 24% below the market average. Zoetis (ZTS), Danaher (DHR), and Accenture (ACN) are expected to lead in returns, with ZTS potentially netting 60.33% with lower-than-market volatility. The dividend dog strategy favors high-yield, contrarian choices.
By Strive MasiyiwaMay 22, 2026
Finance
Millrose Properties: High Yield with Governance Concerns
Millrose Properties, Inc. (MRP) operates as a distinctive land-banking REIT, facilitating asset-light strategies for homebuilders and boasting a substantial 10.88% dividend yield. The company's revenue primarily stems from option fees rather than direct land sales, and it maintains a healthy debt-to-capitalization ratio of 29%. However, significant governance issues, including external management, a high concentration with Lennar, and a dual-class share structure, contribute to a persistent valuation discount. I consider Millrose a speculative Buy for those comfortable with its risks, given its attractive yield and sound balance sheet, despite tight dividend coverage and notable red flags.
By Fareed ZakariaMay 22, 2026
Finance
Dexcom: AI-Powered Medical Platform Driving Innovation and Growth
Dexcom is transforming diabetes management by integrating AI into its Continuous Glucose Monitoring (CGM) systems, enhancing operational efficiency, and fostering product innovation. The company has demonstrated significant financial strength with a 300 basis point improvement in operating margin and robust free cash flow, outperforming industry peers. Its new Stelo CGM, utilizing Google AI, is poised to tap into the large prediabetic market without requiring a prescription, signaling vast expansion potential. Despite potential AI disruption, Dexcom's proprietary data, FDA approvals, and platform strategy establish a strong competitive moat, supporting sustained earnings growth and a target price of $108.
By Strive MasiyiwaMay 22, 2026